FeesSafety
Pluang+

Hyster-Yale reports Q3 bookings up 45%, narrows losses, and expects positive adjusted net income in Q4 2026

Company Fundamentals
05 Nov 2026, 23:30 WIB
PRNewsWire
View Source
Neutral
Hyster-Yale reports Q3 bookings up 45%, narrows losses, and expects positive adjusted net income in Q4 2026

Hyster-Yale's Q3 2026 bookings rose 45% year-over-year to $550 million, marking the fourth consecutive quarter of elevated bookings since mid-2025. Despite a net loss of $14.9 million, the company narrowed its operating loss and returned to positive adjusted EBITDA, driven by improved shipment volumes and cost savings. New operational initiatives launched in Q4 2026 aim to cut costs by $100 million annually by 2029. The company expects stronger Q4 results with adjusted net income turning positive, supported by higher shipments and ongoing pricing and sourcing improvements.

Hyster-Yale's Q3 2026 bookings rose 45% year-over-year to $550 million, highlighting strong order momentum. For readers following Industrials, here is Pluang's market snapshot as of Nov 06, 2026 04:12 WIB: out of 135 priced US Industrials stocks, 13 rose and 122 fell today. Notable movers include FuelCell Energy Inc (FCEL) at USD 8.89 with a 15.65% decline, Rockwell Automation (ROK) at USD 380.00 down 14.43%, and Enovix Corporation (ENVX) at USD 2.39 down 14.34%.

More News

ASUR reports 0.9% decline in total passenger traffic in October 2026 amid mixed regional trends

ASUR reports 0.9% decline in total passenger traffic in October 2026 amid mixed regional trends

Grupo Aeroportuario del Sureste (ASUR) reported a 0.9% decrease in total passenger traffic for October 2026 compared to the previous year, totaling 9.3 million passengers. While Colombia, Puerto Rico, Brazil, and Ecuador saw modest increases in domes...

Market News
Bearish
5 hours ago
BioAge doses first patient in Phase 2 trial for BGE-102 targeting diabetic macular edema; data due 2027

BioAge doses first patient in Phase 2 trial for BGE-102 targeting diabetic macular edema; data due 2027

BioAge Labs initiated dosing in its Phase 2 trial (QUELL-DME) for BGE-102, an oral NLRP3 inhibitor aimed at treating diabetic macular edema, with topline results expected in late 2027. The company also completed enrollment in a Phase 2 cardiovascular...

Company Fundamentals
Bullish
5 hours ago
Vaalco Energy declares Q4 2026 dividend of $0.0625 per share, marking 20 consecutive quarters of payouts.

Vaalco Energy declares Q4 2026 dividend of $0.0625 per share, marking 20 consecutive quarters of payouts.

Vaalco Energy announced a quarterly cash dividend of $0.0625 per share for Q4 2026, payable on December 22, 2026, to shareholders of record as of November 20, 2026. This marks the company's 20th consecutive quarterly dividend, reflecting its strong c...

Company Fundamentals
Bullish
5 hours ago
Mercer International reports improved Q3 EBITDA and enters restructuring to reduce $1.275B debt, raising $400M new capital.

Mercer International reports improved Q3 EBITDA and enters restructuring to reduce $1.275B debt, raising $400M new capital.

Mercer International reported a significant improvement in its third quarter 2026 Operating EBITDA, narrowing losses to negative $2.9 million from negative $28.1 million a year earlier, driven by cost savings and government grants. The company has en...

Company Fundamentals
Neutral
5 hours ago
Ameren raises 2026 earnings guidance, reports Q3 EPS of $2.42, and projects 8-10% annual growth through 2031

Ameren raises 2026 earnings guidance, reports Q3 EPS of $2.42, and projects 8-10% annual growth through 2031

Ameren Corporation reported third quarter 2026 GAAP diluted EPS of $2.42, up from $2.35 in 2025, driven by infrastructure investments and higher electric sales. The company raised its 2026 earnings guidance to $5.35-$5.55 per share and set 2027 guida...

Company Fundamentals
Bullish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App